This article was originally published in The Rose Sheet
Sales of firm's Bull Frog sun care line soared 92% in the third quarter, driven by "increased distribution and display programs and reduced returns," Chattem reports Sept. 17. Selsun blue sales were up 6%, and domestic factory shipments have grown from approximately $20 mil. in 2001 to a projected $34 mil. this year, Chattem states. Bull Frog, Selsun blue, Gold Bond, Icy Hot, Aspercreme and Pamprin led a 12% sales increase to $66.1 mil. in the quarter, which was offset by a 41% decline in Dexatrim sales. Operating income excluding charges related to settlement of litigation concerning Dexatrim with phenylpropanolamine (PPA) was $16.8 mil., up 6%, and net income excluding litigation settlement charges advanced 36% to $9.3 mil. Firm also announces it will introduce a number of new products under Bull Frog, pHisoderm and Gold Bond brands...
You may also be interested in...
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.
Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.